.ANALYSIS HIGHLIGHT.16 October 2024.
In the NIAGARA trial, the addition of perioperative durvalumab to conventional treatment for muscle-invasive sac cancer cells improved event-free as well as overall survival, marking a brand-new therapy alternative for this problem.